GSK outlines accelerated R&D, operations simplification, pipeline funding
GSK says it is accelerating R&D and simplifying operations to drive GBP 2 billion in savings, funding a pipeline across HIV long-acting injectables, oncology and liver disease innovations.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.